# Bioreperia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioreperia

- Industry: Biotechnology
- Headquarters: Linkoping, Sweden
- Website: www.bioreperia.com
- Total disclosed funding: $0.9M
- Latest round: Series A (Jun 28, 2019)
- Investors on record: 2

## About

Bioreperia AB specializes in innovative oncology solutions, leveraging its proprietary ZTX® platform to enhance drug discovery and patient-specific treatment options for cancer therapy.Founded in 2015 in Linkoping, Sweden, Bioreperia AB focuses on oncology drug discovery, utilizing its unique ZTX® platform. The company has not undergone significant strategic pivots and does not have known subsidiaries. Its founding team includes Anna Fahlgren, while Anna Erkstam serves as the CEO. In June 2019, Bioreperia raised SEK 8 million in a Series A funding round, which was co-led by ALMI Invest and Hemex Health, Inc., as the company’s first significant investment target. The total amount raised to date is SEK 8 million.BioReperia offers oncology solutions through its proprietary ZTX® platform, which encompasses ZTX™ ONCOLEADS and ZTX™ PREDICT. ZTX™ ONCOLEADS is an in-vivo drug discovery tool that accurately mimics the tumor microenvironment for rapid selection of lead candidates, while ZTX™ PREDICT tailors cancer treatment recommendations based on individual patient profiles. The company serves biopharmaceutical entities, clinical researchers, and healthcare providers in North America, Europe, and Asia, fostering collaborations with academic and biotech firms to advance cancer therapies.In the most recent year, 2024, Bioreperia reported a revenue of SEK 365,237.70, with an EBITDA of -SEK 422,064.80. The company generates revenue through partnerships and service agreements with biopharmaceutical companies and research institutions, providing access to its ZTX® platform on a contractual basis, while its primary products support customized drug discovery and diagnostic services.Following the SEK 8 million Series A funding round completed in June 2019, Bioreperia aims to expand its product offerings and enhance its platform capabilities. The company is focused on designing new solutions to improve oncology drug discovery, although specific upcoming product release dates have not been disclosed. Bioreperia also plans to enter new geographic markets, specifically targeting Asia and North America, by 2025. The recent funding will be utilized to support the development of new products and market expansion initiatives.

## Funding rounds

- Series A, Jun 28, 2019, $0.9M — ALMI Invest, Hemex Health, Inc.

## Investors

- ALMI Invest — Series A
- Hemex Health, Inc. — Series A